Brian Leber

16.3k total citations · 3 hit papers
196 papers, 9.5k citations indexed

About

Brian Leber is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Brian Leber has authored 196 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Hematology, 90 papers in Molecular Biology and 64 papers in Genetics. Recurrent topics in Brian Leber's work include Acute Myeloid Leukemia Research (52 papers), Cell death mechanisms and regulation (41 papers) and Chronic Lymphocytic Leukemia Research (40 papers). Brian Leber is often cited by papers focused on Acute Myeloid Leukemia Research (52 papers), Cell death mechanisms and regulation (41 papers) and Chronic Lymphocytic Leukemia Research (40 papers). Brian Leber collaborates with scholars based in Canada, United States and United Kingdom. Brian Leber's co-authors include David W. Andrews, Aisha Shamas‐Din, Justin Kale, Lieven P. Billen, Matthew G. Annis, Jialing Lin, Linda Z. Penn, Silvia Bacchetti, Jonathan F. Lovell and Jyothi Gupta and has published in prestigious journals such as Nature, Cell and Journal of Biological Chemistry.

In The Last Decade

Brian Leber

188 papers receiving 9.4k citations

Hit Papers

Mitochondrio‐nuclear tran... 1995 2026 2005 2015 2000 2013 1995 200 400 600

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Brian Leber 6.3k 1.6k 1.3k 1.2k 1.1k 196 9.5k
Anthony D. Whetton 5.2k 0.8× 1.6k 1.0× 1.4k 1.1× 1.2k 1.0× 886 0.8× 277 8.9k
Lucio Cocco 8.8k 1.4× 1.3k 0.8× 1.8k 1.4× 1.2k 1.0× 719 0.6× 344 12.0k
Bernard Payrastre 7.1k 1.1× 2.7k 1.7× 994 0.8× 1.6k 1.3× 1.1k 1.0× 270 12.9k
Vincent W. Yang 9.6k 1.5× 850 0.5× 1.4k 1.1× 785 0.6× 572 0.5× 192 12.9k
Patrick Auberger 6.5k 1.0× 1.1k 0.7× 2.1k 1.7× 1.9k 1.5× 627 0.6× 193 10.5k
Jan‐Gowth Chang 4.4k 0.7× 787 0.5× 940 0.7× 526 0.4× 1.6k 1.4× 329 8.2k
Silvano Capitani 4.8k 0.8× 975 0.6× 1.3k 1.0× 1.6k 1.3× 421 0.4× 262 7.9k
Agostino Tafuri 4.3k 0.7× 2.0k 1.2× 1.7k 1.3× 2.3k 1.8× 631 0.6× 160 8.3k
Aviv Gazit 5.3k 0.8× 1.0k 0.6× 3.3k 2.6× 1.3k 1.0× 920 0.8× 99 9.7k
Richard A. Franklin 5.8k 0.9× 789 0.5× 2.4k 1.9× 1.2k 1.0× 496 0.4× 146 9.5k

Countries citing papers authored by Brian Leber

Since Specialization
Citations

This map shows the geographic impact of Brian Leber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Leber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Leber more than expected).

Fields of papers citing papers by Brian Leber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Leber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Leber. The network helps show where Brian Leber may publish in the future.

Co-authorship network of co-authors of Brian Leber

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Leber. A scholar is included among the top collaborators of Brian Leber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Leber. Brian Leber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berg, Tobias, et al.. (2025). Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma. Current Oncology. 32(2). 118–118.
2.
Buckstein, Rena, Jeannie Callum, Anca Prica, et al.. (2024). Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC‐ENHANCE. Transfusion. 64(2). 223–235. 1 indexed citations
3.
Radford, M, Daria Grafodatskaya, M. Elizabeth McCready, et al.. (2024). Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS. Transplantation and Cellular Therapy. 31(2). 77.e1–77.e20. 3 indexed citations
4.
Singh, Kanwaldeep, Emily Hartung, Islam Alshamleh, et al.. (2023). LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism. Blood. 142(Supplement 1). 4156–4156. 1 indexed citations
5.
Buckstein, Rena, Karen Yee, Michelle Geddes, et al.. (2023). The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma. 64(3). 651–661. 3 indexed citations
6.
Mozessohn, Lee, Ning Liu, Brian Leber, et al.. (2023). Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice. 19(4). e559–e569. 3 indexed citations
7.
Nguyen, Dang, et al.. (2023). The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes. eLife. 12. 5 indexed citations
8.
Salter, Brittany, et al.. (2023). The successful management of acute promyelocytic leukemia during pregnancy: a case report. Leukemia & lymphoma. 65(4). 526–529. 1 indexed citations
9.
Yan, Yu, Kanwaldeep Singh, Emily Hartung, et al.. (2023). LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses. Blood. 142(Supplement 1). 6793–6793. 1 indexed citations
10.
Boyd, Allison L., Justin Lu, Jennifer Reid, et al.. (2023). Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Cell Reports Medicine. 4(7). 101108–101108. 6 indexed citations
11.
Tizhoosh, Hamid R., et al.. (2021). A BERT model generates diagnostically relevant semantic embeddings from pathology synopses with active learning. Communications Medicine. 1(1). 11–11. 14 indexed citations
14.
Arnold, Donald M., et al.. (2018). Cyclic thrombocytopenia with statistically significant neutrophil oscillations. Clinical Case Reports. 6(7). 1347–1352. 9 indexed citations
15.
16.
Hughes, Timothy P., Gabriel Étienne, Cármino Antônio De Souza, et al.. (2012). Nilotinib induces deeper molecular responses vs continued imatinib in patients with ph+ chronic myeloid leukemia (CML) with detectable disease after ≥ 2 years on imatinib: ENESTcmr 12-months results. Haematologica. 97. 239–239.
17.
Owen, Carolyn, Cynthia L. Toze, Donna L. Forrest, et al.. (2008). Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood. 112(12). 4639–4645. 168 indexed citations
18.
Geng, Fei, Weijia Zhu, Brian Leber, & David W. Andrews. (2006). Multiple post-translational modifications of E-cadherin during ER stress and apoptosis. Cancer Research. 66. 44–44. 3 indexed citations
19.
Leber, Brian & Silvia Bacchetti. (1996). Telomeres and Telomerase in Normal and Malignant Haematologic Cells. Leukemia & lymphoma. 24(1-2). 1–9. 26 indexed citations
20.
Hirsh, Richard F., et al.. (1978). Fornix fibers and motivational states as controllers of behavior: A study stimulated by the contextual retrieval theory. Behavioral Biology. 22(4). 463–478. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026